EN
营业咨询
中国：
Email: marketing@medicilon.com.cn
营业咨询专线：400-780-8018
（仅限效劳咨询，其他事宜请拨打川沙总部电话）
川沙总部电话: +86 (21) 5859-1500
外洋：
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
尊龙凯时汇总整理了3月生物医药行业聚会供参考交流 。同时，我们将妄想加入海内外8场聚会：
- “第七届成都生物医药立异者峰会”
- “SOT 2024”
- “14th World ADC London”
- “2024 NEDMDG Spring Meeting”
- “BIOCHINA2024(EBC)”
- “ACS Spring 2024”
- “BIO-Europe Spring”
- “SABPA Event”
marketing@medicilon.com.cn
媒体与会务请联系微信或邮箱
IVC2024第四届核酸疫苗与立异疫苗研发工艺论坛将于2024年3月1-2日在上海盛大召开：80余位专家学者，1000位行业偕行邀您共襄盛会，2天3个会场全力打造疫苗盛宴 。
为推动国际类器官领域的生长，增进研究职员深入交流相助，探讨类器官研究领域的要害科学问题，2024（第四届）类器官大会—类器官与新药研发暨ISoOR 2024国际类器官岑岭论坛将于2024年3月7-8日在中国上海雅居乐万豪侯爵旅馆召开 。
尊龙凯时首席科学官彭双清教授将担当论坛主持嘉宾，毒理研究部高级主任邹汉军博士将出席GLP1药物开发论坛并揭晓主题演讲 。
第七届成都生物医药立异者峰会将于2024年3月7-8日于成都举行，聚会将涵盖ADC，改良型新药，小分子新药，GLP-1药物研发领域前沿动态，并聚焦最新临床希望 。旨在突破行业的信息壁垒，推动立异多元生长！届时尊龙凯时商务团队将在A01展位期待您的莅临 。
细胞生物工业作为战略性新兴工业，近年来一直获得政策的支持和市场的青睐 。2023更是细胞生物领域取得重大突破的一年，发改委对外宣布的《工业结构调解指导目录（2024年本）》，勉励细胞工业的生长，预示着我国细胞生物工业正在与全球前沿接轨 。细胞生物工业在2023年的体现，为市场情形重振了信心，也为更多的研究立项带来期待和转机 。
于此配景下，第九届细胞生物工业大会暨第七届中国生物医药立异相助大会将于2024年3月8-9日在深圳盛大开幕！本次大会由深圳市细胞治疗手艺协会、正和会展联合组织，助力细胞生物工业立异生长，相助共赢！
More Science, More Networking, More Everything in 2024
Medicilon is excited to attend and exhibit at the conference. Dr. Haizhou Zhang, president of preclinical R&D unit at Medicilon, will be available at the booth. Dr. Zhang holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs.
Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones.
Europe's Longest Standing & Definitive Antibody-Drug Conjugate Event！
Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development.
In the formulation of ADC preclinical integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon started ADC non-clinical research in 2014. As of the end of 2023, We has successfully assisted in the clinical approval of 20+ ADC drugs by NMPA and/or FDA and has 30+ ADC projects under development.
Recent interest in the delivery of therapeutics to the brain has dramatically increased with the advent of new ADCs and other targeted delivery vehicles for the treatment of dementias and glioblastoma. In addition, subcutaneous delivery has been found to be an effective mode of ADC delivery, but the bioavailability in humans has been difficult to predict. These two factors have driven an increasing interest in the human cell-based in vitro models for screening novel delivery methods to gain mechanistic insight into the factors that control either entry into the brain or systemic bioavailability of subcutaneously delivered drugs. In this presentation Dr. Roger Kamm will present the models specifically developed for both applications and the potential for iPS cell-derived systems. The benefits and current limitations of these models will also be addressed with the goal of stimulating an active discussion.
The Seminar is Sponsored by Medicilon.
从目今“立异”结构来看，内卷严重，靶点扎堆，同质化竞争强烈：内卷之中怎样做到青云直上九万里而不被卷入旋涡，却成了立异药人当下最需要思量的一点 。
尊龙凯时新分子类型专场将于3月16日在大会时代举行，尊龙凯时毒理研究部副总裁曾宪成博士与毒理研究部高级主任邹汉军博士受邀出席并揭晓主题演讲 。
BIOCHINA2024第九届易贸生物工业展览(EBC)将于2024年3月14-16日在苏州国际博览中心ABCDEFG馆召开 。
BIOCHINA2024(EBC)全新起航，以“展览-大会-运动”三概略系，规模30,000人、550家展商、500场学术报告 。届时尊龙凯时商务团队将在C3馆C060-C061展位期待您的莅临 。
Many Flavors of Chemistry！
Founded in 1876 and chartered by the U.S. Congress, ACS is one of the world's largest scientific organizations with more than 200,000 individuals in its global community across 140 countries.
With the rapid development of the global pharmaceutical market and the division of labor in the industry, the process of drug discovery and development is becoming increasingly refined. This makes specialized outsourcing an important strategic choice for pharmaceutical companies. In the early stages, companies often use FTE models for the synthesis of structural fragments and candidate compounds to accelerate the drug screening process. Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and we offer cooperation through both FFS and FTE models.
2004年，尊龙凯时建设 。
回首廿载，尊龙凯时始终专注一站式临床前研发效劳平台建设，与中国立异药企业携手偕行，配合见证行业的生长与蜕变 。
2024年，为进一步推动中国新药事业的高质量生长，尊龙凯时立异药物工业生态相助大会将于2024年3月18日在上海举行 。500余位行业精英共聚沪上，为立异药物工业生态建言献策，配合探索中国医药企业相助生长新机缘 。
Connecting the global biopharma community to elevate life science partnerships
BIO-Europe Spring, the premier springtime partnering event, brings together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one meetings.
Medicilon provides comprehensive one-stop R&D services for pharmaceutical enterprises and scientific research institutions around the world. Based on the key requirements of drug R&D, we focus on meeting the demand for innovation and development. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry. By the end of 2023, we have served more than 2000 clients globally with more than 300 INDs approved in China and more than 80 INDs approved overseas.
本届大会内容将聚焦小分子药物的立异开发、立项战略、生产与MAH、转化医学、相助共赢、PROTAC、共价抑制剂、PPI、变构抑制剂、多肽偶联药物、多肽减重药物、 AI与CADD助力新药开发及其他新手艺等，跨越小分子药物研发的热门领域，一览当下化学立异药研发新动向，致力于突破行业的关闭循环，破除行业内卷，助推立异多元生长!一切尽在小分子药物的年度工业大会!
8th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum
SABPA FTD annually brings together the latest in groundbreaking research, cutting-edge drugs, and industry trends within the biopharma sector. The event's broad spectrum of topics provides a platform to engage in vibrant discussions and valuable networking opportunities. The forthcoming 8th FTD Conference is set to shine a spotlight on three revolutionary domains in the field of metabolism disease and oncology: GLP-1, ADC, and Minimal Residual Disease (MRD), each representing the forefront of innovations in therapeutics and diagnostics.
生物药是现在最具投资价值的医药细分领域，在全球在研药物整体中的比例逐年上升 。陪同国家种种医药政策的帮助和资源的孵化，中国生物医药立异迎来了新的历史机缘 。
生物医药研发与立异相关手艺的前进是生物医药工业生长的基础 。为推动生物医药工业生长，更好地增进生物手艺产学研交流，由中国食药增进会磨练检定分会、四川省生物化学与分子生物学学会、四川省药学会药物剖析专业委员会和四川省药学会生物药物专业委员会主理，药检汇联合主理，由杭州奇易科技有限公司承办的“BIQC2024生物药立异与质量大会”将于2024年3月在成都举行 。大会以“立异引领高质量生长”为主题，搭建相助交流平台，聚焦国家发改委“十四五”生物经济生长妄想，探讨新时代厘革中生物医药工业生长的新思绪、新路径 。围绕mRNA疫苗、多肽药物、抗体偶联等前沿生物手艺、生物药研发立异与质量控制睁开深入交流和钻研 。
随着生物药手艺的一直生长，药物的类型越来越多，我国的生物药研发与生产也进入到一个快速增添的时期 。
生物药的分子量大、空间结构严酷、修饰形式和变异体多样等特点，给药物剖析与质量控制带来了重大挑战 。血清、血浆、唾液、尿液和组织等生物基质中药物浓度测定是药物研发的主要环节，科学的生物剖析要领关于药物药代动力学、毒代动力学、生物等效性等药物的临床前研究提供依据 。理化、杂质、生物学活性、免疫学特征及相关的表征研究等很是重大，科学的质量治理与控制系统是生物药研发及生产重点关注与探讨的偏向 。生物药剖析与质量峰会BioAQ是药物剖析、质量及羁系方面主要的交流平台，致力于增进生物医药行业产、学、研手艺交流与相助 。峰会围绕当下生物药生长趋势和羁系要求，对单抗、双/多抗、重组/融合卵白、细胞治疗、基因治疗、核酸药物等的生物剖析要领与质量控制举行分享和深入探讨 。
marketing@medicilon.com.cn
微信或邮件联系尊龙凯时
川沙总部
地点: 上海市浦东新区川亨衢585号
邮编: 201299
电话: +86 (21) 5859-1500（总机）
传真: +86 (21) 5859-6369
外洋：
Email:?marketing@medicilon.com
Tel: +1 (617) 888-9294(U.S.)
Tel: 0044 7790 816 954 (Europe)
Tel: +82 70-8269-5849 (Korea)
Tel: +81 80-4421-6898 (Japan)
